Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.66 |
| ▸ | TP53 | P04637 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14513163 | 0.89 | MAPT (0.67) | MAPTTP53SMN1; SMN2NPC1NFKB1 | |
| SCHEMBL4380477 | 0.88 | MAPT (0.64) | MAPTTP53SMN1; SMN2NPC1NFKB1 | |
| SCHEMBL28711032 | 0.85 | ALOX15 (0.74) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13240441 | 0.84 | MAPT (0.66) | MAPTTP53SMN1; SMN2NPC1NFKB1 | |
| SCHEMBL13265765 | 0.84 | MAPT (0.63) | MAPTTP53SMN1; SMN2NPC1NFKB1 | |
| SCHEMBL16681664 | 0.84 | ALOX15 (0.73) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4144380 | 0.84 | ALOX15 (0.72) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12176917 | 0.83 | MAPT (0.63) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31502646 | 0.83 | MAPT (0.65) | MAPTTP53SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20353853 | 0.83 | MAPT (0.70) | MAPTTP53SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| EP-1492783-A1 | 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | Axxima Pharmaceuticals AG (DE) | 2005-01-05 | — | — | EP | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | claimed |
| US-9284295-B2 | Tetrahydrobenzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-9284295-B2 | Tetrahydrobenzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-03-15 | — | — | US | disclosed |
| EP-2565190-B1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| EP-2565190-B1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-20140329802-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140329802-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20130029973-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029973-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| WO-2011136269-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | アステラス製薬株式会社 (JP) | 2011-11-03 | — | — | WO | disclosed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329802-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | SLC34A2, SLC34A1, SLC10A2 | MAPT 1262/4885TP53 2863/4885SMN1; SMN2 4680/4885 |
| US-20130029973-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | SLC34A2, SLC10A2, SLC34A1 | MAPT 257/4885TP53 3359/4885SMN1; SMN2 3732/4885 |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | MAPT 3062/4885TP53 1772/4885SMN1; SMN2 4741/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | MAPT 21/4885TP53 2520/4885SMN1; SMN2 2157/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | MAPT 2046/4885TP53 1999/4885SMN1; SMN2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.